Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus

Infection, Genetics and Evolution

Volumn 8, Issue 1, 2008, Pages 74-82

  Torres Puente, Manuela ^a   Cuevas, José M ^a   Jiménez Hernández, Nuria ^a,b   Bracho, María Alma ^a,b   García Robles, Inmaculada ^a   Wrobel, Borys ^a   Carnicer, Fernando ^c   del Olmo, Juan ^d   Ortega, Enrique ^e   Moya, Andrés ^a,b   González Candelas, Fernando ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Antiviral treatment; E1 E2 region; HCV; Hypervariable region; Non responder patient; Positive selection

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; GLYCOPROTEIN E2; PEGINTERFERON; RIBAVIRIN; VIRUS ENVELOPE PROTEIN;

AMINO ACID COMPOSITION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS GENOME;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; COMPLEMENTARITY DETERMINING REGIONS; EVOLUTION; HEPACIVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; RNA, VIRAL; VARIATION (GENETICS); VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 36749070008     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2007.10.005     Document Type: Article

References (39)

1. Boulestin A., Sandres-Saune K., Payen J.L., Alric L., Dubois M., Pasquier C., Vinel J.P., Pascal J.P., Puel J., and Izopet J. Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha. J. Med. Virol. 68 (2002) 221-228
2. Bracho M.A., Carrillo-Cruz F.Y., Ortega E., Moya A., and González-Candelas F. A new subtype of hepatitis C virus genotype 1: complete genome and phylogenetic relationships of an Equatorial Guinea isolate. J. Gen. Virol. 87 (2006) 1697-1702
3. Brown R.J., Juttla V.S., Tarr A.W., Finnis R., Irving W.L., Hemsley S., Flower D.R., Borrow P., and Ball J.K. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J. Gen. Virol. 86 (2005) 1931-1942
4. Brown R.J., Tarr A.W., McClure C.P., Juttla V.S., Tagiuri N., Irving W.L., and Ball J.K. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J. Gen. Virol. 88 (2007) 458-469
5. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
6. Choo Q.L., Richman K.H., Han J.H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P.J., Weiner A.J., Bradley D.W., Kuo G., and Houghton M. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2451-2455
7. Drummer H.E., Boo I., Maerz A.L., and Poumbourios P. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 80 (2006) 7844-7853
8. Dutoit V., Ciuffreda D., Comte D., Gonvers J.J., and Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur. J. Immunol. 35 (2005) 3493-3504
9. Farci P., and Purcell R.H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liver Dis. 20 (2000) 103-126
10. Flint M., Maidens C., Loomis-Price L.D., Shotton C., Dubuisson J., Monk P., Higginbottom A., Levy S., and McKeating J.A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73 (1999) 6235-6244
11. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
12. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S21-S29
13. Kato N., Ootsuyama Y., Tanaka T., Nakagawa M., Nakazawa T., Muraiso K., Ohkoshi S., Hijikata M., and Shimotohno K. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res. 22 (1992) 107-123
14. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., and Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67 (1993) 3923-3930
15. Korber B., and Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8 (1992) 1549-1560
16. Kosakovsky Pond S.L., and Frost S.D.W. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 22 (2005) 1208-1222
17. Kosakovsky Pond S.L., Frost S.D.W., and Muse S.V. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21 (2005) 676-679
18. Kuiken C., Combet C., Bukh J., Shin I., Deleage G., Mizokami M., Richardson R., Sablon E., Yusim K., Pawlotsky J.M., and Simmonds P. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 44 (2006) 1355-1361
19. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
20. McHutchison J.G., and Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 19 Suppl. 1 (1999) 57-65
21. Reed K.E., and Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242 (2000) 55-84
22. Saito S., Kato N., Hijikata M., Gunji T., Itabashi M., Kondo M., Tanaka K., and Shimotohno K. Comparison of hypervariable regions (HVR1 and HVR2) in positive- and negative-stranded hepatitis C virus RNA in cancerous and non-cancerous liver tissue, peripheral blood mononuclear cells and serum from a patient with hepatocellular carcinoma. Int. J. Cancer 67 (1996) 199-203
23. Sheridan I., Pybus O.G., Holmes E.C., and Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 78 (2004) 3447-3454
24. Shirai M., Arichi T., Chen M., Masaki T., Nishioka M., Ikeda K., Takahashi H., Enomoto N., Saito T., Major M.E., Nakazawa T., Akatsuka T., Feinstone S.M., and Berzofsky J.A. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J. Immunol. 162 (1999) 568-576
25. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85 (2004) 3173-3188
26. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., and Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005) 962-973
27. Sokal R.R., and Rohlf F.J. Biometry. 3rd ed. (1995), W.H. Freeman, New York, NY
28. Staden R., Beal K.F., and Bonfield J.K. The Staden package, 1998. Methods Mol. Biol. 132 (2000) 115-130
29. Taniguchi S., Okamoto H., Sakamoto M., Kojima M., Tsuda F., Tanaka T., Munekata E., Muchmore E.E., Peterson D.A., and Mishiro S. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195 (1993) 297-301
30. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
31. Torres-Puente M., Cuevas J.M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Contribution of insertions and deletions to the variability of hepatitis C virus populations. J. Gen. Virol. 88 (2007) 2198-2203
32. Troesch M., Meunier I., Lapierre P., Lapointe N., Alvarez F., Boucher M., and Soudeyns H. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352 (2006) 357-367
33. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q.L., and Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 (1991) 842-848
34. Weiner A.J., Geysen H.M., Christopherson C., Hall J.E., Mason T.J., Saracco G., Bonino F., Crawford K., Marion C.D., and Crawford K.A. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 3468-3472
35. Wong D.K., Dudley D.D., Afdhal N.H., Dienstag J., Rice C.M., Wang L., Houghton M., Walker B.D., and Koziel M.J. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J. Immunol. 160 (1998) 1479-1488
36. Yagnik A.T., Lahm A., Meola A., Roccasecca R.M., Ercole B.B., Nicosia A., and Tramontano A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40 (2000) 355-366
37. Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput. Appl. Biosci. 13 (1997) 555-556
38. Yang Z., Nielsen R., Goldman N., and Pedersen A.M. Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155 (2000) 431-449
39. Zhang P., Wu C.G., Mihalik K., Virata-Theimer M.L., Yu M.Y., Alter H.J., and Feinstone S.M. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8449-8454